108 related articles for article (PubMed ID: 30582279)
1. Oxaprozin: A new hope in the modulation of matrix metalloproteinase 9 activity.
Ianni A; Celenza G; Franceschini N
Chem Biol Drug Des; 2019 May; 93(5):811-817. PubMed ID: 30582279
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into the binding mode of flavonols with the active site of matrix metalloproteinase-9 through molecular docking and molecular dynamic simulations studies.
Pradiba D; Aarthy M; Shunmugapriya V; Singh SK; Vasanthi M
J Biomol Struct Dyn; 2018 Nov; 36(14):3718-3739. PubMed ID: 29068268
[TBL] [Abstract][Full Text] [Related]
3. Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9.
Omanakuttan A; Nambiar J; Harris RM; Bose C; Pandurangan N; Varghese RK; Kumar GB; Tainer JA; Banerji A; Perry JJ; Nair BG
Mol Pharmacol; 2012 Oct; 82(4):614-22. PubMed ID: 22745359
[TBL] [Abstract][Full Text] [Related]
4. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
5. Salvianolic Acid B Strikes Back: New Evidence in the Modulation of Expression and Activity of Matrix Metalloproteinase 9 in MDA-MB-231 Human Breast Cancer Cells.
Ianni A; Ruggeri P; Bellio P; Martino F; Celenza G; Martino G; Franceschini N
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500603
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity.
Tochowicz A; Maskos K; Huber R; Oltenfreiter R; Dive V; Yiotakis A; Zanda M; Pourmotabbed T; Bode W; Goettig P
J Mol Biol; 2007 Aug; 371(4):989-1006. PubMed ID: 17599356
[TBL] [Abstract][Full Text] [Related]
7. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Gelatinases (MMP-2 and MMP-9) by Withania somnifera Phytochemicals Confers Neuroprotection in Stroke: An In Silico Analysis.
Kumar G; Patnaik R
Interdiscip Sci; 2018 Dec; 10(4):722-733. PubMed ID: 28488219
[TBL] [Abstract][Full Text] [Related]
9. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
[TBL] [Abstract][Full Text] [Related]
10. Construction, expression, and characterization of a baculovirally expressed catalytic domain of human matrix metalloproteinase-9.
Sadatmansoori S; MacDougall J; Khademi S; Cooke LS; Guarino L; Meyer EF; Forough R
Protein Expr Purif; 2001 Dec; 23(3):447-52. PubMed ID: 11722182
[TBL] [Abstract][Full Text] [Related]
11. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade.
Vandooren J; Van den Steen PE; Opdenakker G
Crit Rev Biochem Mol Biol; 2013; 48(3):222-72. PubMed ID: 23547785
[TBL] [Abstract][Full Text] [Related]
12. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Laghezza A; Tortorella P; Agamennone M
ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
[TBL] [Abstract][Full Text] [Related]
13. Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3.
Geurts N; Martens E; Van Aelst I; Proost P; Opdenakker G; Van den Steen PE
Biochemistry; 2008 Feb; 47(8):2689-99. PubMed ID: 18237197
[TBL] [Abstract][Full Text] [Related]
14. New in Vivo Compatible Matrix Metalloproteinase (MMP)-2 and MMP-9 Inhibitors.
Beutel B; Song J; Konken CP; Korpos E; Schinor B; Gerwien H; Vidyadharan R; Burmeister M; Li L; Haufe G; Sorokin L
Bioconjug Chem; 2018 Nov; 29(11):3715-3725. PubMed ID: 30277751
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies.
Kalva S; Azhagiya Singam ER; Rajapandian V; Saleena LM; Subramanian V
J Mol Graph Model; 2014 Apr; 49():25-37. PubMed ID: 24473069
[TBL] [Abstract][Full Text] [Related]
16. Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2.
Xu X; Chen Z; Wang Y; Yamada Y; Steffensen B
Biochem J; 2005 Nov; 392(Pt 1):127-34. PubMed ID: 16008524
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms.
Bellini T; Trentini A; Manfrinato MC; Tamborino C; Volta CA; Di Foggia V; Fainardi E; Dallocchio F; Castellazzi M
J Biochem; 2012 May; 151(5):493-9. PubMed ID: 22343748
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and discovery of (I-3,II-3)-biacacetin as a novel non-zinc binding inhibitor of MMP-2 and MMP-9.
Nanjan P; Nambiar J; Nair BG; Banerji A
Bioorg Med Chem; 2015 Jul; 23(13):3781-7. PubMed ID: 25907368
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of quercetin on matrix metalloproteinase 9 activity molecular mechanism and structure-activity relationship of the flavonoid-enzyme interaction.
Saragusti AC; Ortega MG; Cabrera JL; Estrin DA; Marti MA; Chiabrando GA
Eur J Pharmacol; 2010 Oct; 644(1-3):138-45. PubMed ID: 20619256
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains.
Martens E; Leyssen A; Van Aelst I; Fiten P; Piccard H; Hu J; Descamps FJ; Van den Steen PE; Proost P; Van Damme J; Liuzzi GM; Riccio P; Polverini E; Opdenakker G
Biochim Biophys Acta; 2007 Feb; 1770(2):178-86. PubMed ID: 17137715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
